Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice of non-compliance with minimum bid price requirement and faces potential delisting by September 2026.
- Going Concern (new) — Auditor expressed substantial doubt about the company's ability to continue as a going concern in the 2025 audit report due to recurring losses and limited cash runway.
Skye Bioscience faces Nasdaq delisting risk; Phase 2a monotherapy missed endpoint
Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read
Key Changes
-
high
Nasdaq issued deficiency notice March 17, 2026 for stock trading below $1.00 for 30 days; company has until Sept 14 to regain compliance or face delisting, plans reverse stock split requiring shareholder approval
Controls & Procedures verify on EDGAR → -
high
Auditor raised going concern doubt in 2025 audit; cash declined $8.6M in Q1 to $17.1M, providing runway only through Q4 2026 excluding Phase 2b costs
MD&A: Liquidity verify on EDGAR → -
high
Phase 2a monotherapy missed primary weight loss endpoint (-1.52% vs -0.26% placebo); dose deemed suboptimal, prompting new expansion study testing 400mg and 600mg IV doses with Q4 2026 data expected
MD&A: Clinical Results verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade SKYE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify